Opus Genetics (IRD) Free Cash Flow Growth (1y) (2011 - 2026)
Opus Genetics (IRD) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 137.65% |
| 10 | Opus Genetics | 280.66 Mn | 220.66 Mn | - | -41.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.51% |
| Dec 31, 2025 | -32.20% |
| Sep 30, 2025 | -20.02% |
| Jun 30, 2025 | -40.83% |
| Mar 31, 2025 | -57.35% |
| Dec 31, 2024 | -263.54% |
| Sep 30, 2024 | -70.83% |
| Jun 30, 2024 | -837.31% |
| Mar 31, 2024 | -56.77% |
| Dec 31, 2023 | -84.20% |
| Sep 30, 2023 | 33.24% |
| Jun 30, 2023 | 125.96% |
| Mar 31, 2023 | 40.91% |
| Dec 31, 2022 | 609.94% |
| Sep 30, 2022 | -25.50% |
| Jun 30, 2022 | 11.99% |
| Mar 31, 2022 | -6.16% |
| Dec 31, 2021 | -29.55% |
| Sep 30, 2021 | -239.39% |
| Jun 30, 2021 | -564.82% |